XFOR
X4 Pharmaceuticals, Inc
$4.00
+3.09%
$377.3M
No data for this timeframe.
Vol
Market Cap$377.3M
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (89%)
Inst. Holders32 funds
Inst. Value$122.0M
Inst. Activity4 buys / 4 sells
Insider Activity0B / 1S
Insider Net $-$72.8K
SEC Reports7
Press Releases1
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. DE·CIK 0001501697·Prev Close $3.88
Recent Activity
Jun 11, 2026
SEC
An institutional cluster in X4 Pharmaceuticals shows mixed conviction in Q3 2025, with two mega-passive buyers (Vanguard
INST-CLUSTER — Impact 2/10
Jun 11, 2026
SEC
Five major institutional investors (Vanguard, BlackRock, State Street, Fidelity, Morgan Stanley) collectively added $84.
INST-CLUSTER — Impact 3/10
Jun 1, 2026
other
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.co
May 18, 2026
SEC
X4 Pharmaceuticals' S-3 shelf registration (File No. 333-295597) became effective on May 14, 2026, enabling the company
EFFECT — Impact 4/10
May 12, 2026
Insider
KIRSKE DAVID sold 16,961 shares
Chief Financial Officer @ $4.29 ($72.8K)
Inst.
STATE STREET CORP — DOUBLED
403,534 shares ($1.7M)
Inst.
MARSHALL WACE, LLP — DOUBLED
336,834 shares ($1.4M)
Mar 17, 2026
Press
X4 Pharmaceuticals reported Q4 and full-year 2025 financial results with $35.1M in total revenue, driven by a $28.6M lic
Impact 6/10
Price Targets
$11.75
+193.8% upside
Strong Buy
Current $4.00
Low $10.00
Median $12.00
High $13.00
4 analysts
$10.00
$13.00
Analyst Ratings
4Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jun 2, 2026 | Leerink Partners | INITIATE | Outperform |
| Mar 9, 2026 | Guggenheim | INITIATE | Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.19 ▲ +9.5% | $-0.22 — $-0.17 | 95% YoY | 4 |
| Next Q | $-0.20 ▲ +10.2% | $-0.27 — $-0.17 | 71% YoY | 4 |
| Current FY | $-0.76 ▲ +13.5% | $-0.96 — $-0.67 | 60% YoY | 4 |
| Next FY | $-0.91 ▲ +5.4% | $-1.05 — $-0.84 | -21% YoY | 3 |
Latest Reports
NEUTRAL
INST-CLUSTER
2/10
An institutional cluster in X4 Pharmaceuticals shows mixed conviction in Q3 2025, with two mega-passive buyers (Vanguard
Jun 11, 2026
NEUTRAL
INST-CLUSTER
3/10
Five major institutional investors (Vanguard, BlackRock, State Street, Fidelity, Morgan Stanley) collectively added $84.
Jun 11, 2026
MIXED
Press
6/10
X4 Pharmaceuticals reported Q4 and full-year 2025 financial results with $35.1M in total revenue, driven by a $28.6M lic
Mar 17, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| ROYAL BANK OF CANADA | — | ADD |
| MORGAN STANLEY | $39.1M | DOUBLED |
| FMR LLC | $33.5M | NEW |
| VANGUARD CAPITAL MANAGEMENT LLC | $14.4M | — |
| Blackstone Inc. | $11.1M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 12, 2026 | KIRSKE DAVID | SELL | $72.8K |
32 institutional holders with $122.0M total value (29,531,715 shares) as of 2026-Q1. Top holders: ROYAL, MORGAN, FMR.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | ROYAL BANK OF CANADA | 115 | $0.00 | 0.0% | ADD +43.6% |
| 2 | MORGAN STANLEY | 9,466,992 | $39.1M | 32.1% | DOUBLED +220072.1% |
| 3 | FMR LLC | 8,103,400 | $33.5M | 27.4% | NEW |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 3,497,612 | $14.4M | 11.8% | — |
| 5 | Blackstone Inc. | 2,681,922 | $11.1M | 9.1% | NEW |
| 6 | BlackRock, Inc. | 1,211,794 | $5.0M | 4.1% | DOUBLED +1880.8% |
| 7 | Woodline Partners LP | 1,001,095 | $4.1M | 3.4% | — |
| 8 | GOLDMAN SACHS GROUP INC | 882,134 | $3.6M | 3.0% | — |
| 9 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 856,222 | $3.5M | 2.9% | — |
| 10 | VANGUARD FIDUCIARY TRUST CO | 480,733 | $2.0M | 1.6% | — |
| 11 | STATE STREET CORP | 403,534 | $1.7M | 1.4% | DOUBLED +103.6% |
| 12 | MARSHALL WACE, LLP | 336,834 | $1.4M | 1.1% | DOUBLED +318.7% |
| 13 | BANK OF AMERICA CORP /DE/ | 150,676 | $622.3K | 0.5% | DOUBLED +321.3% |
| 14 | Brevan Howard Capital Management LP | 127,321 | $525.8K | 0.4% | — |
| 15 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 66,749 | $275.7K | 0.2% | — |
| 16 | OMERS ADMINISTRATION Corp | 57,300 | $236.6K | 0.2% | TRIM -47.5% |
| 17 | Hudson Bay Capital Management LP | 50,287 | $207.7K | 0.2% | ADD +56.0% |
| 18 | CITIGROUP INC | 35,765 | $147.7K | 0.1% | DOUBLED +242.1% |
| 19 | Vanguard Global Advisers, LLC | 32,977 | $136.2K | 0.1% | — |
| 20 | STIFEL FINANCIAL CORP | 21,789 | $90.0K | 0.1% | TRIM -38.3% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| STATE STREET CORP | DOUBLED | 198,234 | 403,534 | +103.6% | $1.7M | 2026-Q1 |
| MARSHALL WACE, LLP | DOUBLED | 80,456 | 336,834 | +318.7% | $1.4M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 35,761 | 150,676 | +321.3% | $622.3K | 2026-Q1 |
| OMERS ADMINISTRATION Corp | TRIM | 109,200 | 57,300 | -47.5% | $236.6K | 2026-Q1 |
| Hudson Bay Capital Management LP | ADD | 32,239 | 50,287 | +56.0% | $207.7K | 2026-Q1 |
| ExodusPoint Capital Management, LP | NEAR_EXIT | 79,072 | 14,703 | -81.4% | $60.7K | 2026-Q1 |
| GROUP ONE TRADING LLC | NEAR_EXIT | 3,998 | 712 | -82.2% | $2.9K | 2026-Q1 |
| Allworth Financial LP | TRIM | 715 | 310 | -56.6% | $1.3K | 2026-Q1 |
| FMR LLC | NEW | — | 8,499,100 | — | $34.0M | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 3,728 | 8,208,015 | +220072.1% | $32.8M | 2025-Q4 |
| VANGUARD GROUP INC | DOUBLED | 410,485 | 3,423,662 | +734.1% | $13.7M | 2025-Q4 |
| Blackstone Inc. | NEW | — | 2,681,922 | — | $10.7M | 2025-Q4 |
| BlackRock, Inc. | DOUBLED | 61,934 | 1,226,808 | +1880.8% | $4.9M | 2025-Q4 |
| Point72 Asset Management, L.P. | DOUBLED | 21,666 | 808,154 | +3630.1% | $3.2M | 2025-Q4 |
| STATE STREET CORP | DOUBLED | 38,734 | 198,234 | +411.8% | $792.9K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 19,304 | 35,761 | +85.3% | $143.0K | 2025-Q4 |
| VANGUARD GROUP INC | ADD | 231,892 | 410,485 | +77.0% | $1.4M | 2025-Q3 |
| UBS Group AG | ADD | 109,959 | 159,835 | +45.4% | $546.6K | 2025-Q3 |
| BlackRock, Inc. | TRIM | 179,228 | 61,934 | -65.4% | $211.8K | 2025-Q3 |
| STATE STREET CORP | DOUBLED | 15,534 | 38,734 | +149.3% | $132.5K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 80,316 | 19,304 | -76.0% | $66.0K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 10,924 | 3,728 | -65.9% | $12.8K | 2025-Q3 |
| Russell Investments Group, Ltd. | NEAR_EXIT | 9,727 | 729 | -92.5% | $2.5K | 2025-Q3 |
| UBS Group AG | DOUBLED | 923,060 | 5,037,183 | +445.7% | $1.2M | 2025-Q1 |
| BANK OF AMERICA CORP /DE/ | TRIM | 133,502 | 77,340 | -42.1% | $18.3K | 2025-Q1 |
1 unique insiders with 1 transactions. Net insider value: -$72.8K ($0.00 bought, $72.8K sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 12, 2026 | KIRSKE DAVID | Chief Financial Officer | SELL | 16,961 | $4.29 | $72.8K |
7 SEC filing reports analyzed. Sentiment: 0 bullish, 0 bearish, 1 mixed, 6 neutral. Avg impact: 3.0/10.
NEUTRAL
INST-CLUSTER
2/10
An institutional cluster in X4 Pharmaceuticals shows mixed conviction in Q3 2025, with two mega-pass
Jun 11, 2026
NEUTRAL
INST-CLUSTER
3/10
Five major institutional investors (Vanguard, BlackRock, State Street, Fidelity, Morgan Stanley) col
Jun 11, 2026
NEUTRAL
EFFECT
4/10
X4 Pharmaceuticals' S-3 shelf registration (File No. 333-295597) became effective on May 14, 2026, e
May 18, 2026
NEUTRAL
144
2/10
David Kirske, an officer of X4 Pharmaceuticals, filed a Form 144 notice of intent to sell 16,961 sha
May 12, 2026
NEUTRAL
8-K
2/10
X4 Pharmaceuticals held its 2026 annual meeting on May 11, 2026, where stockholders approved an amen
May 12, 2026
MIXED
PRESS-RELEASE
6/10
X4 Pharmaceuticals reported Q1 2026 revenue of $2.7M (vs $3.2M consensus) and GAAP EPS of -$0.16 (vs
May 6, 2026
NEUTRAL
DEFA14A
2/10
Analysis based on filing metadata only — document content was unavailable
Mar 20, 2026
Current analyst consensus: Strong Buy (89% buy). Based on 9 analysts: 4 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$11.75 mean target
+193.8% upside
Strong Buy (1.00)
$10.00 Low
$13.00 High
| Metric | Value |
|---|---|
| Current Price | $4.00 |
| Target Low | $10.00 |
| Target Mean | $11.75 |
| Target Median | $12.00 |
| Target High | $13.00 |
| # Analysts | 4 |
| Recommendation | Strong Buy (1.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.19 | $-0.22 | $-0.17 | 94.5% | +9.5% | — | $0.0B | 15.3% | 4 |
| Next Q 2026-09-30 |
$-0.20 | $-0.27 | $-0.17 | 71.4% | +10.2% | — | $0.0B | 31.7% | 4 |
| Current FY 2026-12-31 |
$-0.76 | $-0.96 | $-0.67 | 59.6% | +13.5% | 2↑ 0↓ | $0.0B | -72.9% | 4 |
| Next FY 2027-12-31 |
$-0.91 | $-1.05 | $-0.84 | -21.0% | +5.4% | 1↑ 0↓ | $0.0B | 0.8% | 3 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.190 | |
| 7d ago | $-0.190 | |
| 30d ago | $-0.210 | +0.020 |
| 60d ago | $-0.210 | +0.020 |
| 90d ago | $-0.220 | +0.030 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Jun 2, 2026 | Leerink Partners | INITIATE | — | Outperform |
| Mar 9, 2026 | Guggenheim | INITIATE | — | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 4 | 1 | 0 | 0 | 89% | |
| May 1, 2026 | 4 | 4 | 1 | 0 | 0 | 89% | |
| Apr 1, 2026 | 4 | 4 | 1 | 0 | 0 | 89% | |
| Mar 1, 2026 | 3 | 5 | 1 | 0 | 0 | 89% | |
| Feb 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% | |
| Jan 1, 2026 | 3 | 6 | 1 | 0 | 0 | 90% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 1, 2026
other
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=-fg0J-QuumGhaB-IwBMVV-84Hd7eXV8MZQS
May 6, 2026
earnings
X4 Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Corporate Update
<p align="center"><em>- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment by the end of Q3 2026 -</em></p>
Apr 29, 2026
earnings_calendar
XFOR Q1 2026 Earnings Scheduled — 2026-04-29
Apr 1, 2026
other
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=9tYPT-WmImzHA3MSHLUE5uwFre8Kp3tdmF
Mar 23, 2026
earnings_calendar
XFOR Q4 2025 Earnings After Market Close — 2026-03-23
Mar 17, 2026
earnings
X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
<p align="center"><em>- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 -</em></p>
Mar 4, 2026
other
X4 Pharmaceuticals to Participate in a Fireside Chat at the Leerink Global Healthcare Conference
<p align="justify">BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=YscyKJeZGabCevQbJhQUH4NomgKyMaUAkl
Mar 2, 2026
other
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
<p align="justify">BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=aTdxKsSHQ_r9dP-FX3GpIC9oJ1j7OgAISQ